- Home
- FENC
as 05-30-2025 4:00pm EST
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | RESEARCH TRIANGLE PARK |
| Market Cap: | 156.9M | IPO Year: | 2001 |
| Target Price: | $13.00 | AVG Volume (30 days): | 105.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.53 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.96 - $8.56 | Next Earning Date: | 05-13-2025 |
| Revenue: | $30,912,000 | Revenue Growth: | -31.23% |
| Revenue Growth (this year): | -1.37% | Revenue Growth (next year): | 58.65% |
Stock Insider Trading Activity of Fennec Pharmaceuticals Inc. (FENC)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hackman Jeffrey S. | FENC | Chief Executive Officer | May 16 '25 | Buy | $6.87 | 15,000 | $104,601.60 | 1,035 | |
| Raykov Rosty | FENC | Director | May 5 '25 | Sell | $6.31 | 10,000 | $63,100.00 | 53,587 | |
| RALLIS CHRIS A | FENC | Director | Apr 11 '25 | Sell | $4.95 | 1,409 | $6,974.55 | 53,784 | |
| Raykov Rosty | FENC | Director | Apr 4 '25 | Sell | $5.25 | 10,000 | $52,500.00 | 53,587 | |
| Raykov Rosty | FENC | Director | Mar 5 '25 | Sell | $6.79 | 10,000 | $67,900.00 | 53,587 |
Latest Fennec Pharmaceuticals Inc. News
FENC Breaking Stock News: Dive into FENC Ticker-Specific Updates for Smart Investing
Simply Wall St.
17 days ago
Fennec Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations
GuruFocus.com
18 days ago
Fennec Pharmaceuticals Inc (FENC) Q1 2025 Earnings Call Highlights: Strong Sales Growth Amid ...
Thomson Reuters StreetEvents
18 days ago
Q1 2025 Fennec Pharmaceuticals Inc Earnings Call
MT Newswires
19 days ago
Fennec Swings to Q1 Loss on Lower Revenue, but Pedmark Sales up; Shares 10% Higher in U.S. Pre-market
GlobeNewswire
19 days ago
Fennec Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
23 days ago
Fennec Pharmaceuticals to Report First Quarter 2025 Financial Results on May 13, 2025
Simply Wall St.
a month ago
Recent uptick might appease Fennec Pharmaceuticals Inc. (NASDAQ:FENC) hedge funds owners after losing 32% over the past year
Simply Wall St.
2 months ago
Breakeven Is Near for Fennec Pharmaceuticals Inc. (NASDAQ:FENC)
Compare FENC vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FENC Fennec Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.